Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative or Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Conditions: Bilateral Breast Carcinoma; Breast Carcinoma; HER2/Neu Negative; Mastectomy Patient; Recurrent Breast Carcinoma; Triple-Negative Breast Carcinoma Interventions: Drug: ATR Kinase Inhibitor M6620; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | HER2 | Radiation Therapy | Research